Ezetimibe and LGD-4033 Interaction

Avoid
Mechanism-based 64% confidence

Ezetimibe and LGD-4033 have a potentially harmful interaction with 64% confidence. Both Ezetimibe and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the heart, so monitoring these systems is recommended.

Compound Profiles

Ezetimibe

Cholesterol Absorption Inhibitor | Lipid Management On Cycle

Ezetimibe selectively inhibits the NPC1L1 transporter protein located on the luminal surface of enterocytes in the jejunum of the small intestine. NPC1L1 is the critical gateway for intestinal cholesterol absorption, responsible for uptaking both dietary cholesterol and the much larger pool of biliary cholesterol that is recirculated through the enterohepatic cycle.

Half-life: ~22 hours Typical dose: 10 mg/day cardiovascular
npc1l1 hepatotoxiclipid disruptingteratogenic
View full profile

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Combined Organ Load

Heart
moderate
Gonads
moderate
Liver
moderate

Shared Safety Flags

2x 2 hepatotoxic compounds (Ezetimibe, LGD-4033). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds disrupt lipids (Ezetimibe, LGD-4033). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (Ezetimibe, LGD-4033). Monitor accordingly.

Frequently Asked Questions

Can I take Ezetimibe with LGD-4033?

Combining Ezetimibe with LGD-4033 is not recommended. Both Ezetimibe and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Ezetimibe and LGD-4033 safe together?

This combination carries significant risk. Both Ezetimibe and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Ezetimibe and LGD-4033?

Both Ezetimibe and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Ezetimibe and LGD-4033?

Ezetimibe has a half-life of ~22 hours and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Ezetimibe vs LGD-4033

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.